PDA Industry and Honor Award Winners

I have been actively involved with the association since 2008 when I was working at the FDA. For the past three years, I have been involved in the APAC region, so an award from such a reputable organization that supports the pharma industry means a lot to me. It validates my work, provides credibility and helps my reputation as an expert in the pharmaceutical quality area.

The recognition from PDA, peers and colleagues enhances my professional role as an advocate within the industry and my company. In such a heavily regulated industry, I am proud to help advance pharmaceutical manufacturing and quality. Industry recognition is meaningful because it represents trust, in myself and my organization. 

For me, my work is personal. I lost my sister and father to cancer because there was no access to effective drugs at the time in China. High-quality drugs should be available in all developing countries to ensure healthcare and to save lives. 

I plan to continue to share my experience and knowledge with the industry and professionals in the pharmaceutical industry. For me, it is important to bridge the world of science to the real world to help patients in need.

Dr. Qui's division was also responsible for conducting pre-license/pre-approval inspections for CDER regulated biological products. Prior to CDER, he also worked in FDA’s Center for Biologics Evaluation and Research (CBER) as a CMC facility reviewer/inspector and in the Center for Devices and Radiological Health (CDRH) as an Associate Director for Toxicology.

Dr. Qiu graduated from the University of Southern California with a Ph.D. in Biological Sciences and worked at Innovent Biologics (SuZhou) as the Chief Quality Officer before joining Roche Genentech. 

I have been actively involved with the association since 2008 when I was working at the FDA. For the past three years, I have been involved in the APAC region, so an award from such a reputable organization that supports the pharma industry means a lot to me. It validates my work, provides credibility and helps my reputation as an expert in the pharmaceutical quality area.

The recognition from PDA, peers and colleagues enhances my professional role as an advocate within the industry and my company. In such a heavily regulated industry, I am proud to help advance pharmaceutical manufacturing and quality. Industry recognition is meaningful because it represents trust, in myself and my organization. 

For me, my work is personal. I lost my sister and father to cancer because there was no access to effective drugs at the time in China. High-quality drugs should be available in all developing countries to ensure healthcare and to save lives. 

I plan to continue to share my experience and knowledge with the industry and professionals in the pharmaceutical industry. For me, it is important to bridge the world of science to the real world to help patients in need.

Dr. Qui's division was also responsible for conducting pre-license/pre-approval inspections for CDER regulated biological products. Prior to CDER, he also worked in FDA’s Center for Biologics Evaluation and Research (CBER) as a CMC facility reviewer/inspector and in the Center for Devices and Radiological Health (CDRH) as an Associate Director for Toxicology.

Dr. Qiu graduated from the University of Southern California with a Ph.D. in Biological Sciences and worked at Innovent Biologics (SuZhou) as the Chief Quality Officer before joining Roche Genentech. 

I have been actively involved with the association since 2008 when I was working at the FDA. For the past three years, I have been involved in the APAC region, so an award from such a reputable organization that supports the pharma industry means a lot to me. It validates my work, provides credibility and helps my reputation as an expert in the pharmaceutical quality area.

The recognition from PDA, peers and colleagues enhances my professional role as an advocate within the industry and my company. In such a heavily regulated industry, I am proud to help advance pharmaceutical manufacturing and quality. Industry recognition is meaningful because it represents trust, in myself and my organization. 

For me, my work is personal. I lost my sister and father to cancer because there was no access to effective drugs at the time in China. High-quality drugs should be available in all developing countries to ensure healthcare and to save lives. 

I plan to continue to share my experience and knowledge with the industry and professionals in the pharmaceutical industry. For me, it is important to bridge the world of science to the real world to help patients in need.

Dr. Qui's division was also responsible for conducting pre-license/pre-approval inspections for CDER regulated biological products. Prior to CDER, he also worked in FDA’s Center for Biologics Evaluation and Research (CBER) as a CMC facility reviewer/inspector and in the Center for Devices and Radiological Health (CDRH) as an Associate Director for Toxicology.

Dr. Qiu graduated from the University of Southern California with a Ph.D. in Biological Sciences and worked at Innovent Biologics (SuZhou) as the Chief Quality Officer before joining Roche Genentech. 

I have been actively involved with the association since 2008 when I was working at the FDA. For the past three years, I have been involved in the APAC region, so an award from such a reputable organization that supports the pharma industry means a lot to me. It validates my work, provides credibility and helps my reputation as an expert in the pharmaceutical quality area.

The recognition from PDA, peers and colleagues enhances my professional role as an advocate within the industry and my company. In such a heavily regulated industry, I am proud to help advance pharmaceutical manufacturing and quality. Industry recognition is meaningful because it represents trust, in myself and my organization. 

For me, my work is personal. I lost my sister and father to cancer because there was no access to effective drugs at the time in China. High-quality drugs should be available in all developing countries to ensure healthcare and to save lives. 

I plan to continue to share my experience and knowledge with the industry and professionals in the pharmaceutical industry. For me, it is important to bridge the world of science to the real world to help patients in need.

Dr. Qui's division was also responsible for conducting pre-license/pre-approval inspections for CDER regulated biological products. Prior to CDER, he also worked in FDA’s Center for Biologics Evaluation and Research (CBER) as a CMC facility reviewer/inspector and in the Center for Devices and Radiological Health (CDRH) as an Associate Director for Toxicology.

Dr. Qiu graduated from the University of Southern California with a Ph.D. in Biological Sciences and worked at Innovent Biologics (SuZhou) as the Chief Quality Officer before joining Roche Genentech. 

I have been actively involved with the association since 2008 when I was working at the FDA. For the past three years, I have been involved in the APAC region, so an award from such a reputable organization that supports the pharma industry means a lot to me. It validates my work, provides credibility and helps my reputation as an expert in the pharmaceutical quality area.

The recognition from PDA, peers and colleagues enhances my professional role as an advocate within the industry and my company. In such a heavily regulated industry, I am proud to help advance pharmaceutical manufacturing and quality. Industry recognition is meaningful because it represents trust, in myself and my organization. 

For me, my work is personal. I lost my sister and father to cancer because there was no access to effective drugs at the time in China. High-quality drugs should be available in all developing countries to ensure healthcare and to save lives. 

I plan to continue to share my experience and knowledge with the industry and professionals in the pharmaceutical industry. For me, it is important to bridge the world of science to the real world to help patients in need.

Dr. Qui's division was also responsible for conducting pre-license/pre-approval inspections for CDER regulated biological products. Prior to CDER, he also worked in FDA’s Center for Biologics Evaluation and Research (CBER) as a CMC facility reviewer/inspector and in the Center for Devices and Radiological Health (CDRH) as an Associate Director for Toxicology.

Dr. Qiu graduated from the University of Southern California with a Ph.D. in Biological Sciences and worked at Innovent Biologics (SuZhou) as the Chief Quality Officer before joining Roche Genentech. 

I have been actively involved with the association since 2008 when I was working at the FDA. For the past three years, I have been involved in the APAC region, so an award from such a reputable organization that supports the pharma industry means a lot to me. It validates my work, provides credibility and helps my reputation as an expert in the pharmaceutical quality area.

The recognition from PDA, peers and colleagues enhances my professional role as an advocate within the industry and my company. In such a heavily regulated industry, I am proud to help advance pharmaceutical manufacturing and quality. Industry recognition is meaningful because it represents trust, in myself and my organization. 

For me, my work is personal. I lost my sister and father to cancer because there was no access to effective drugs at the time in China. High-quality drugs should be available in all developing countries to ensure healthcare and to save lives. 

I plan to continue to share my experience and knowledge with the industry and professionals in the pharmaceutical industry. For me, it is important to bridge the world of science to the real world to help patients in need.

Dr. Qui's division was also responsible for conducting pre-license/pre-approval inspections for CDER regulated biological products. Prior to CDER, he also worked in FDA’s Center for Biologics Evaluation and Research (CBER) as a CMC facility reviewer/inspector and in the Center for Devices and Radiological Health (CDRH) as an Associate Director for Toxicology.

Dr. Qiu graduated from the University of Southern California with a Ph.D. in Biological Sciences and worked at Innovent Biologics (SuZhou) as the Chief Quality Officer before joining Roche Genentech. 

I have been actively involved with the association since 2008 when I was working at the FDA. For the past three years, I have been involved in the APAC region, so an award from such a reputable organization that supports the pharma industry means a lot to me. It validates my work, provides credibility and helps my reputation as an expert in the pharmaceutical quality area.

The recognition from PDA, peers and colleagues enhances my professional role as an advocate within the industry and my company. In such a heavily regulated industry, I am proud to help advance pharmaceutical manufacturing and quality. Industry recognition is meaningful because it represents trust, in myself and my organization. 

For me, my work is personal. I lost my sister and father to cancer because there was no access to effective drugs at the time in China. High-quality drugs should be available in all developing countries to ensure healthcare and to save lives. 

I plan to continue to share my experience and knowledge with the industry and professionals in the pharmaceutical industry. For me, it is important to bridge the world of science to the real world to help patients in need.

Dr. Qui's division was also responsible for conducting pre-license/pre-approval inspections for CDER regulated biological products. Prior to CDER, he also worked in FDA’s Center for Biologics Evaluation and Research (CBER) as a CMC facility reviewer/inspector and in the Center for Devices and Radiological Health (CDRH) as an Associate Director for Toxicology.

Dr. Qiu graduated from the University of Southern California with a Ph.D. in Biological Sciences and worked at Innovent Biologics (SuZhou) as the Chief Quality Officer before joining Roche Genentech. 

I have been actively involved with the association since 2008 when I was working at the FDA. For the past three years, I have been involved in the APAC region, so an award from such a reputable organization that supports the pharma industry means a lot to me. It validates my work, provides credibility and helps my reputation as an expert in the pharmaceutical quality area.

The recognition from PDA, peers and colleagues enhances my professional role as an advocate within the industry and my company. In such a heavily regulated industry, I am proud to help advance pharmaceutical manufacturing and quality. Industry recognition is meaningful because it represents trust, in myself and my organization. 

For me, my work is personal. I lost my sister and father to cancer because there was no access to effective drugs at the time in China. High-quality drugs should be available in all developing countries to ensure healthcare and to save lives. 

I plan to continue to share my experience and knowledge with the industry and professionals in the pharmaceutical industry. For me, it is important to bridge the world of science to the real world to help patients in need.

Dr. Qui's division was also responsible for conducting pre-license/pre-approval inspections for CDER regulated biological products. Prior to CDER, he also worked in FDA’s Center for Biologics Evaluation and Research (CBER) as a CMC facility reviewer/inspector and in the Center for Devices and Radiological Health (CDRH) as an Associate Director for Toxicology.

Dr. Qiu graduated from the University of Southern California with a Ph.D. in Biological Sciences and worked at Innovent Biologics (SuZhou) as the Chief Quality Officer before joining Roche Genentech. 

I have been actively involved with the association since 2008 when I was working at the FDA. For the past three years, I have been involved in the APAC region, so an award from such a reputable organization that supports the pharma industry means a lot to me. It validates my work, provides credibility and helps my reputation as an expert in the pharmaceutical quality area.

The recognition from PDA, peers and colleagues enhances my professional role as an advocate within the industry and my company. In such a heavily regulated industry, I am proud to help advance pharmaceutical manufacturing and quality. Industry recognition is meaningful because it represents trust, in myself and my organization. 

For me, my work is personal. I lost my sister and father to cancer because there was no access to effective drugs at the time in China. High-quality drugs should be available in all developing countries to ensure healthcare and to save lives. 

I plan to continue to share my experience and knowledge with the industry and professionals in the pharmaceutical industry. For me, it is important to bridge the world of science to the real world to help patients in need.

Dr. Qui's division was also responsible for conducting pre-license/pre-approval inspections for CDER regulated biological products. Prior to CDER, he also worked in FDA’s Center for Biologics Evaluation and Research (CBER) as a CMC facility reviewer/inspector and in the Center for Devices and Radiological Health (CDRH) as an Associate Director for Toxicology.

Dr. Qiu graduated from the University of Southern California with a Ph.D. in Biological Sciences and worked at Innovent Biologics (SuZhou) as the Chief Quality Officer before joining Roche Genentech. 

I have been actively involved with the association since 2008 when I was working at the FDA. For the past three years, I have been involved in the APAC region, so an award from such a reputable organization that supports the pharma industry means a lot to me. It validates my work, provides credibility and helps my reputation as an expert in the pharmaceutical quality area.

The recognition from PDA, peers and colleagues enhances my professional role as an advocate within the industry and my company. In such a heavily regulated industry, I am proud to help advance pharmaceutical manufacturing and quality. Industry recognition is meaningful because it represents trust, in myself and my organization. 

For me, my work is personal. I lost my sister and father to cancer because there was no access to effective drugs at the time in China. High-quality drugs should be available in all developing countries to ensure healthcare and to save lives. 

I plan to continue to share my experience and knowledge with the industry and professionals in the pharmaceutical industry. For me, it is important to bridge the world of science to the real world to help patients in need.

Dr. Qui's division was also responsible for conducting pre-license/pre-approval inspections for CDER regulated biological products. Prior to CDER, he also worked in FDA’s Center for Biologics Evaluation and Research (CBER) as a CMC facility reviewer/inspector and in the Center for Devices and Radiological Health (CDRH) as an Associate Director for Toxicology.

Dr. Qiu graduated from the University of Southern California with a Ph.D. in Biological Sciences and worked at Innovent Biologics (SuZhou) as the Chief Quality Officer before joining Roche Genentech. 

I have been actively involved with the association since 2008 when I was working at the FDA. For the past three years, I have been involved in the APAC region, so an award from such a reputable organization that supports the pharma industry means a lot to me. It validates my work, provides credibility and helps my reputation as an expert in the pharmaceutical quality area.

The recognition from PDA, peers and colleagues enhances my professional role as an advocate within the industry and my company. In such a heavily regulated industry, I am proud to help advance pharmaceutical manufacturing and quality. Industry recognition is meaningful because it represents trust, in myself and my organization. 

For me, my work is personal. I lost my sister and father to cancer because there was no access to effective drugs at the time in China. High-quality drugs should be available in all developing countries to ensure healthcare and to save lives. 

I plan to continue to share my experience and knowledge with the industry and professionals in the pharmaceutical industry. For me, it is important to bridge the world of science to the real world to help patients in need.

Dr. Qui's division was also responsible for conducting pre-license/pre-approval inspections for CDER regulated biological products. Prior to CDER, he also worked in FDA’s Center for Biologics Evaluation and Research (CBER) as a CMC facility reviewer/inspector and in the Center for Devices and Radiological Health (CDRH) as an Associate Director for Toxicology.

Dr. Qiu graduated from the University of Southern California with a Ph.D. in Biological Sciences and worked at Innovent Biologics (SuZhou) as the Chief Quality Officer before joining Roche Genentech. 

I have been actively involved with the association since 2008 when I was working at the FDA. For the past three years, I have been involved in the APAC region, so an award from such a reputable organization that supports the pharma industry means a lot to me. It validates my work, provides credibility and helps my reputation as an expert in the pharmaceutical quality area.

The recognition from PDA, peers and colleagues enhances my professional role as an advocate within the industry and my company. In such a heavily regulated industry, I am proud to help advance pharmaceutical manufacturing and quality. Industry recognition is meaningful because it represents trust, in myself and my organization. 

For me, my work is personal. I lost my sister and father to cancer because there was no access to effective drugs at the time in China. High-quality drugs should be available in all developing countries to ensure healthcare and to save lives. 

I plan to continue to share my experience and knowledge with the industry and professionals in the pharmaceutical industry. For me, it is important to bridge the world of science to the real world to help patients in need.

Dr. Qui's division was also responsible for conducting pre-license/pre-approval inspections for CDER regulated biological products. Prior to CDER, he also worked in FDA’s Center for Biologics Evaluation and Research (CBER) as a CMC facility reviewer/inspector and in the Center for Devices and Radiological Health (CDRH) as an Associate Director for Toxicology.

Dr. Qiu graduated from the University of Southern California with a Ph.D. in Biological Sciences and worked at Innovent Biologics (SuZhou) as the Chief Quality Officer before joining Roche Genentech. 

I have been actively involved with the association since 2008 when I was working at the FDA. For the past three years, I have been involved in the APAC region, so an award from such a reputable organization that supports the pharma industry means a lot to me. It validates my work, provides credibility and helps my reputation as an expert in the pharmaceutical quality area.

The recognition from PDA, peers and colleagues enhances my professional role as an advocate within the industry and my company. In such a heavily regulated industry, I am proud to help advance pharmaceutical manufacturing and quality. Industry recognition is meaningful because it represents trust, in myself and my organization. 

For me, my work is personal. I lost my sister and father to cancer because there was no access to effective drugs at the time in China. High-quality drugs should be available in all developing countries to ensure healthcare and to save lives. 

I plan to continue to share my experience and knowledge with the industry and professionals in the pharmaceutical industry. For me, it is important to bridge the world of science to the real world to help patients in need.

Dr. Qui's division was also responsible for conducting pre-license/pre-approval inspections for CDER regulated biological products. Prior to CDER, he also worked in FDA’s Center for Biologics Evaluation and Research (CBER) as a CMC facility reviewer/inspector and in the Center for Devices and Radiological Health (CDRH) as an Associate Director for Toxicology.

Dr. Qiu graduated from the University of Southern California with a Ph.D. in Biological Sciences and worked at Innovent Biologics (SuZhou) as the Chief Quality Officer before joining Roche Genentech. 

I have been actively involved with the association since 2008 when I was working at the FDA. For the past three years, I have been involved in the APAC region, so an award from such a reputable organization that supports the pharma industry means a lot to me. It validates my work, provides credibility and helps my reputation as an expert in the pharmaceutical quality area.

The recognition from PDA, peers and colleagues enhances my professional role as an advocate within the industry and my company. In such a heavily regulated industry, I am proud to help advance pharmaceutical manufacturing and quality. Industry recognition is meaningful because it represents trust, in myself and my organization. 

For me, my work is personal. I lost my sister and father to cancer because there was no access to effective drugs at the time in China. High-quality drugs should be available in all developing countries to ensure healthcare and to save lives. 

I plan to continue to share my experience and knowledge with the industry and professionals in the pharmaceutical industry. For me, it is important to bridge the world of science to the real world to help patients in need.

Dr. Qui's division was also responsible for conducting pre-license/pre-approval inspections for CDER regulated biological products. Prior to CDER, he also worked in FDA’s Center for Biologics Evaluation and Research (CBER) as a CMC facility reviewer/inspector and in the Center for Devices and Radiological Health (CDRH) as an Associate Director for Toxicology.

Dr. Qiu graduated from the University of Southern California with a Ph.D. in Biological Sciences and worked at Innovent Biologics (SuZhou) as the Chief Quality Officer before joining Roche Genentech. 

I have been actively involved with the association since 2008 when I was working at the FDA. For the past three years, I have been involved in the APAC region, so an award from such a reputable organization that supports the pharma industry means a lot to me. It validates my work, provides credibility and helps my reputation as an expert in the pharmaceutical quality area.

The recognition from PDA, peers and colleagues enhances my professional role as an advocate within the industry and my company. In such a heavily regulated industry, I am proud to help advance pharmaceutical manufacturing and quality. Industry recognition is meaningful because it represents trust, in myself and my organization. 

For me, my work is personal. I lost my sister and father to cancer because there was no access to effective drugs at the time in China. High-quality drugs should be available in all developing countries to ensure healthcare and to save lives. 

I plan to continue to share my experience and knowledge with the industry and professionals in the pharmaceutical industry. For me, it is important to bridge the world of science to the real world to help patients in need.

Dr. Qui's division was also responsible for conducting pre-license/pre-approval inspections for CDER regulated biological products. Prior to CDER, he also worked in FDA’s Center for Biologics Evaluation and Research (CBER) as a CMC facility reviewer/inspector and in the Center for Devices and Radiological Health (CDRH) as an Associate Director for Toxicology.

Dr. Qiu graduated from the University of Southern California with a Ph.D. in Biological Sciences and worked at Innovent Biologics (SuZhou) as the Chief Quality Officer before joining Roche Genentech.